Profit machinery upgraded while volume still arriving

DexCom, Inc. (DXCM) — this company's answers

The model's full reasoning — Q4 2023 call → NOWe need to determine if management conveys both: (1) a realized, company-made step-up in per-unit economics, and (2) volume arriving now and early, with most still ahead. From the transcript: Kevin Sayer mentions 2023 accomplishments: revenue growth, EBITDA, new customers, Malaysia plant. He says "we delivered $1 billion in adjusted EBITDA for the year and generated record levels of free cash flow" and "we not only generated $1 billion in Q4 revenue, we also delivered $1 billion in adjusted EBITDA for the year" – that's overall, not per-unit. Jereme Sylvain discusses gross margin: Q4 gross margin 64.2% vs 66.7% year ago, decline due to G7 mix. He says "we expect this to change in the coming quarters as we drive greater volume through our G7 lines. As it reaches scale, we continue to expect G7's margin profile to improve upon that of our G6 platform." That's future expectation, not realized. He also says "we delivered nearly 500 basis points of operating expense leverage compared to last year" – that's cost cutting, but revenue growing. But is that a structural improvement? He says "This quarter was another demonstration of our commitment to being disciplined and thoughtful with our spend. Our operating expenses grew at half the rate of revenue this quarter and we delivered nearly 500 basis points of operating expense leverage compared to last year." That's cost discipline, but not necessarily per-unit economics improvement from company actions like product mix or pricing. It's more about OpEx leverage. He also mentions "we are going to expand that Salesforce" – that's investment, not realized. On volume: They added 600k users, ended with 2.3 million. They talk about basal coverage expansion, G7 launch, etc. They say "we are already seeing more clinicians want to incorporate Dexcom CGM earlier" – that's demand. But is volume arriving now and early? They have guidance for 2024 with growth 16-21%. They say "This guidance assumed continued momentum in the type 2 basal only population in the US, the expansion of Dexcom ONE on the G7 platform into new geographies, and the launch of Stelo in the summer of 2024." That's future. They also say "we are excited to continue our investment in our U.S. salesforce this year" – that's future.

← Back to the full DXCM analysis